Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16442907 | 0.91 | L3MBTL1 (0.31) | MAOBMAOASLC22A12 | |
| SCHEMBL17796255 | 0.88 | SMN1; SMN2 (0.37) | MAOBMAOALMNASLC22A12 | |
| SCHEMBL16442796 | 0.87 | S1PR1 (0.34) | ARMAOBMAOAMRGPRX4BDKRB2 | |
| SCHEMBL16442790 | 0.86 | PPARD (0.38) | — | |
| SCHEMBL16206081 | 0.86 | SLC22A12 (0.33) | MAOBMAOAMRGPRX4SLC22A12 | |
| SCHEMBL17796280 | 0.85 | SLC22A12 (0.32) | MAOBMAOASLC22A12 | |
| SCHEMBL16206100 | 0.85 | PPARG (0.34) | MAOBMAOAMRGPRX4SLC22A12 | |
| SCHEMBL16442786 | 0.84 | PPARD (0.41) | ARLMNAMRGPRX4 | |
| SCHEMBL16442880 | 0.84 | SMN1; SMN2 (0.35) | LMNA | |
| SCHEMBL17808616 | 0.84 | PPARD (0.39) | MAOBMAOAMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3029030-B1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | SUMITOMO CHEMICAL CO (JP) | 2019-09-04 | — | — | EP | disclosed |
| US-9512090-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-9512090-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
| EP-3029030-A1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| EP-3029030-A1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015016373-A1 | TETRAZOLINONE COMPOUND, AND USE THEREFOR | 住友化学株式会社 (JP) | 2015-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159755-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | CYP1A1, CASP1, TCOF1 | AR 988/4885MAOB 2237/4885MAOA 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.